ACUR Stock Overview
An innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Acura Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0023 |
| 52 Week High | US$0.58 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 64.24% |
| 3 Month Change | -39.45% |
| 1 Year Change | 2,201.00% |
| 33 Year Change | -99.54% |
| 5 Year Change | -99.30% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACUR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 9.6% | 2.6% | 0.5% |
| 1Y | 2,201.0% | 13.1% | 30.7% |
Return vs Industry: ACUR exceeded the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: ACUR exceeded the US Market which returned 30.7% over the past year.
Price Volatility
| ACUR volatility | |
|---|---|
| ACUR Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACUR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ACUR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | n/a | Bob Jones | www.acurapharm.com |
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd.
Acura Pharmaceuticals, Inc. Fundamentals Summary
| ACUR fundamental statistics | |
|---|---|
| Market cap | US$152.67k |
| Earnings (TTM) | -US$879.00k |
| Revenue (TTM) | US$1.56m |
0.0x
P/S Ratio0.0x
P/E RatioIs ACUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACUR income statement (TTM) | |
|---|---|
| Revenue | US$1.56m |
| Cost of Revenue | US$1.52m |
| Gross Profit | US$39.00k |
| Other Expenses | US$918.00k |
| Earnings | -US$879.00k |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ACUR perform over the long term?
See historical performance and comparison